Sanofi: A Leader In Life-Saving Vaccines And Treatments

Investment thesis Wall Street's indifference to France's largest pharmaceutical company is reflected in its share price continuing to move sideways despite its rich pipeline of approved and experimental medicines, rising dividend payouts, and relatively low debt. In my estimation, in addition to the product candidates, some of which could become "gold standards" in the treatment of autoimmune diseases, other key contributors to strengthening Sanofi's balance sheet are innovative drugs such as Dupixent, Nexv ...